Document is current
Any future updates will be listed below
-
Authors
Ekhtiari, Hamed https://orcid.org/0000-0001-6902-8798
Sangchooli, Arshiya
Carmichael, Owen
Moeller, F. Gerard
O’Donnell, Patricio
Oquendo, Maria A.
Paulus, Martin P. https://orcid.org/0000-0002-0825-3606
Pizzagalli, Diego A. https://orcid.org/0000-0002-7772-1143
Ramey, Tatiana
Schacht, Joseph P. https://orcid.org/0000-0003-4250-0495
Zare-Bidoky, Mehran
Childress, Anna Rose
Brady, Kathleen
- License Information
-
More Information
Article History
Received: 9 June 2023
Accepted: 19 September 2024
First Online: 18 November 2024
Competing interests
: O.C. has received grant funding from Eli Lilly and Nestle. He has provided paid consulting to Novo Nordisk. Over the past 3 years, D.A.P. has received consulting fees from Boehringer Ingelheim, Compass Pathways, Engrail Therapeutics, Neumora Therapeutics (formerly BlackThorn Therapeutics), Neurocrine Biosciences, Neuroscience Software, Sage Therapeutics, Sama Therapeutics and Takeda; he has received honoraria from the American Psychological Association, Psychonomic Society and Springer (for editorial work) and from Alkermes; he has received research funding from the BIRD Foundation, Brain and Behavior Research Foundation, Dana Foundation, DARPA, Millennium Pharmaceuticals, NIMH and Wellcome Leap MCPsych; and he has received stock options from Compass Pathways, Engrail Therapeutics, Neumora Therapeutics and Neuroscience Software. M.P.P. is an adviser to Spring Care, a behavioral health startup; he has received royalties for an article about methamphetamine in UpToDate and he has a consulting agreement with, and receives compensation from, F. Hoffmann–La Roche. P.O. is an employee and shareholder of Sage Therapeutics. All other authors declare no competing interests.
